GILEAD SCIENCES INC (GILD)

US3755581036 - Common Stock

92.4  -1.71 (-1.82%)

GILEAD SCIENCES INC

NASDAQ:GILD (12/30/2024, 12:13:07 PM)

92.4

-1.71 (-1.82%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-11.79%
Sales Q2Q%7.01%
CRS78.81
6 Month37.17%
Overview
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-04 2025-02-04/amc
Ins Owners0.07%
Inst Owners87.91%
Market Cap115.16B
Shares1.25B
PE20.86
Fwd PE12.01
Dividend Yield3.26%
Analysts77.44
Short Float %1.88%
Short Ratio3.6
IPO01-22 1992-01-22
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GILD Daily chart

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 18,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. The company is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The firm operates in more than 35 countries.

Company Info

GILEAD SCIENCES INC

333 Lakeside Dr

Foster City CALIFORNIA 94404

P: 16505743000

CEO: Daniel P. O'Day

Employees: 18000

Website: https://www.gilead.com/

GILD News

News Image4 days ago - Zacks Investment ResearchGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

ChartMill News Image5 days ago - ChartmillBased on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout.

GILEAD SCIENCES INC (NASDAQ:GILD) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

News Image10 days ago - Gilead Sciences, Inc.Gilead Sciences to Present at Upcoming Investor Conference
News Image10 days ago - Zacks Investment ResearchGilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

News Image10 days ago - Zacks Investment ResearchIs Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.

News Image10 days ago - Investor's Business DailyIs Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

GILD Twits

Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example